Intra-Cellular Therapies, Inc.

Merger-and-acquisition activity in the biopharmaceutical sector had almost nowhere to go but up in the first quarter of 2025, following a historically low quarter in terms of total potential deal valu

Two companies of similar economic scale and each with its own troubled financial history revealed plans to merge on 13 March, as privately held Mallinckrodt and publicly traded Endo will combine into

Entering 2025, biopharma industry observers expected an uptick of merger-and-acquisition activity, coming off a 2024 that saw some historic lows for such activity. Hopes were raised with some sizeab

Despite notable advancements in Alzheimer’s disease treatment during the last five years, the therapeutic area remains a complex and uncertain area for drug developers. Approvals for the first disease